Pharma-Bio Serv, Inc. (PBSV)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Pharma-Bio Serv, Inc. (PBSV) trades at $0.56 with AI Score 45/100 (Grade C). Pharma-Bio Serv, Inc. Market cap: $12.94M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for PBSV: PBSV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PBSV against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PBSV: the 1 perspectives are evenly split.
How is this calculated? →Pharma-Bio Serv, Inc. (PBSV) Healthcare & Pipeline Overview
Pharma-Bio Serv, Inc. is a specialized consulting firm offering critical regulatory compliance, system validation, and technology transfer services to diverse clients in the pharmaceutical, biotechnology, medical device, cosmetic, and food sectors. Operating across multiple geographies, the company supports complex industry needs with its technical advisory expertise.
What Is the Investment Thesis for PBSV?
Pharma-Bio Serv, Inc. (PBSV) operates within a critical niche, providing specialized regulatory compliance and technology transfer services to highly regulated industries such as pharmaceuticals, biotechnology, and medical devices. The company's value proposition is anchored in its deep expertise and established operational presence across Puerto Rico, the US, Europe, and Brazil, serving a diverse client base since 1993. Key growth catalysts include the ongoing increase in global regulatory complexity, driving sustained demand for expert compliance assistance, and the robust expansion of the biopharmaceutical industry, which necessitates continuous system validation and technology transfer support for new product pipelines. Financially, PBSV exhibits a gross margin of 32.5%, reflecting the profitability of its specialized consulting services. However, the company currently reports a negative profit margin of -0.9%, indicating challenges in achieving overall net profitability. With a market capitalization of $12.94M, PBSV is a micro-cap entity, and its OTC Other listing presents inherent risks related to liquidity and access to capital. The reported dividend yield of 13.27% warrants close scrutiny given the negative profit margin. Investors evaluating PBSV should focus on its ability to leverage industry growth trends into sustainable profitability and navigate the unique challenges of its OTC market listing.
Based on FMP financials and quantitative analysis
PBSV Key Highlights
- Market Capitalization: $0.01 billion, indicating a micro-cap company with a small public float.
- Gross Margin: 32.5%, reflecting the profitability of its specialized consulting services before operating expenses.
- Profit Margin: -0.9%, indicating the company is currently operating at a net loss.
- Dividend Yield: 13.27%, an exceptionally high figure that warrants further investigation given the negative profit margin.
- Employee Count: 75 employees, suggesting a specialized and lean operational structure for a consulting firm.
Who Are PBSV's Competitors?
PBSV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CARL CARLSMED, INC. | $11.90 | +4.94% | $323.50M | 70 |
| HNGE Hinge Health, Inc. | $89.42 | +6.39% | $6.92B | 68 |
| VRHI Veri Medtech Holdings Inc. | $1.95 | +0.00% | $39.09M | 67 |
| AKLI Akili, Inc. | $0.43 | +0.25% | $34.10M | 67 |
| RCM R1 RCM Inc. | $14.31 | +0.00% | $6.04B | 54 |
| BFRG Bullfrog AI Holdings, Inc. Common Stock | $0.72 | +3.54% | $8.46M | 54 |
| CERN Cerner Corporation | $94.92 | +0.00% | 54 | |
| CRVW CareView Communications, Inc. | $0.05 | -8.31% | $30.65M | 54 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PBSV's Key Strengths?
- Specialized expertise in regulatory compliance and technology transfer for highly regulated industries.
- Diverse client base spanning pharmaceutical, biotechnology, medical device, cosmetic, and food sectors.
- Established international operational reach across Puerto Rico, the US, Europe, and Brazil.
- Long operational history since its establishment in 1993, indicating experience and stability.
What Are PBSV's Weaknesses?
- Negative profit margin of -0.9%, indicating current operational challenges to achieving net profitability.
- Micro-cap market capitalization of $12.94M, which can imply limited resources and market influence.
- OTC Other listing, which typically entails challenges related to liquidity and access to capital.
- Reliance on project-based work, which can lead to revenue variability.
What Could Drive PBSV Stock Higher?
- Increasing global regulatory complexity across the pharmaceutical, biotechnology, and medical device industries, driving sustained demand for specialized compliance services.
- Continued expansion and innovation within the biopharmaceutical sector, necessitating expert system validation and technology transfer support for new product development.
- The growing trend of outsourcing specialized, non-core functions by life science companies, creating a sustained market for Pharma-Bio Serv's consulting expertise.
- Potential for new significant client acquisitions or expansion into new regulated market segments, leveraging the company's established international presence.
What Are the Key Risks for PBSV?
- Negative profit margin of -0.9%, indicating operational challenges in achieving overall net profitability and potentially impacting long-term financial stability.
- Challenges associated with its OTC Other listing, including limited liquidity, wide bid-ask spreads, and potential difficulty in accessing capital markets for growth.
- Intense competition from larger, more established consulting firms and other specialized consultancies in the highly fragmented healthcare services market.
- Economic downturns or budget constraints within client industries, which could lead to reduced spending on consulting services and project delays.
- Adverse changes in regulatory frameworks that could simplify compliance requirements or reduce the need for specific specialized services offered by the company.
What Are the Growth Opportunities for PBSV?
- Increasing Regulatory Scrutiny: Global regulatory bodies, such as the FDA, EMA, and ANVISA, are continuously tightening compliance standards across the pharmaceutical, biotechnology, and medical device industries. This escalating regulatory complexity creates a persistent and growing demand for specialized consulting services. Pharma-Bio Serv, Inc.'s core expertise in regulatory adherence and system validation directly addresses this need, positioning the company to assist clients in navigating evolving requirements, ensuring product safety, efficacy, and market access. The ongoing nature of regulatory updates provides a sustained revenue stream for compliance-focused consultancies.
- Biopharmaceutical R&D Expansion: The biopharmaceutical industry is experiencing significant investment in research and development, leading to a robust pipeline of new drugs, therapies, and biological products. Each stage of this development, from preclinical to commercialization, requires extensive validation, regulatory submission, and quality assurance processes. Pharma-Bio Serv's proficiency in technology transfer, system validation, and engineering solutions is crucial for these companies, as they bring innovative products to market, directly increasing the need for the company's specialized support services.
- Digital Transformation in Healthcare: The healthcare and life sciences sectors are increasingly adopting digital technologies, including artificial intelligence, the Internet of Things (IoT), and cloud computing, for R&D, manufacturing, and supply chain management. The integration of these advanced technologies necessitates new validation protocols, data integrity frameworks, and compliance strategies. Pharma-Bio Serv's expertise in system validation and technology migration positions it uniquely to guide clients through this digital transformation, ensuring that new digital infrastructures meet stringent regulatory requirements while enhancing operational efficiency.
- Global Market Expansion for Clients: As pharmaceutical, biotechnology, and medical device companies expand their operations and supply chains into international markets, they encounter a complex patchwork of diverse national and regional regulations. Pharma-Bio Serv's established operational reach across Puerto Rico, the United States, Europe, and Brazil provides a significant competitive advantage. This geographic presence enables the company to offer clients seamless support for multi-jurisdictional compliance projects and technology transfers, facilitating their global market entry and expansion strategies.
- Outsourcing of Non-Core Functions: A prevailing trend in the life sciences sector is the increasing outsourcing of specialized, non-core functions such as regulatory affairs, quality assurance, and engineering solutions. Companies aim to focus their internal resources on core competencies like drug discovery and commercialization, relying on external experts for highly specialized and resource-intensive tasks. This trend creates a sustained and expanding market for consulting firms like Pharma-Bio Serv, which can offer cost-effective, expert-driven solutions without the overhead associated with maintaining large in-house departments.
What Opportunities Does PBSV Have?
- Growing demand for specialized services driven by increasing global regulatory complexity in life sciences.
- Expansion of the biopharmaceutical industry, creating a need for validation and technology transfer expertise.
- Digital transformation in healthcare requiring new compliance and validation frameworks.
- Increasing trend of outsourcing non-core functions by life science companies to specialized consultants.
What Threats Does PBSV Face?
- Intense competition from larger, more established consulting firms and other specialized consultancies.
- Economic downturns or budget cuts by clients potentially impacting demand for consulting services.
- Changes in regulatory frameworks that could simplify compliance, potentially reducing the need for some services.
- Challenges associated with its OTC Other listing, including low trading volume and difficulty raising capital.
What Are PBSV's Competitive Advantages?
- Specialized expertise in complex regulatory compliance and technology transfer, difficult to replicate quickly.
- Established operational presence across multiple international regions (US, Europe, Brazil, Puerto Rico), facilitating global client support.
- Long-standing client relationships built on trust and successful project delivery since its founding in 1993.
- Ability to serve a diverse range of highly regulated industries, from pharmaceuticals to food, broadening market reach.
What Does PBSV Do?
Established in 1993 and headquartered in Dorado, Puerto Rico, Pharma-Bio Serv, Inc. operates as a highly specialized consulting firm dedicated to serving the intricate needs of regulated industries. The company's core expertise lies in providing comprehensive services centered on regulatory compliance and the efficient transfer of technology. Pharma-Bio Serv extends its compliance and technical advisory services to a broad spectrum of clients, encompassing the pharmaceutical, chemical, biotechnology, medical device, cosmetic, and food industries, along with other related product companies. This diverse client base underscores the universal demand for stringent regulatory adherence across various sectors dealing with sensitive products. Pharma-Bio Serv's operational footprint is geographically extensive, reaching across Puerto Rico, the United States, Europe, and Brazil, enabling it to support clients with multi-jurisdictional projects and international regulatory requirements. The firm's technical advisory offerings are robust and multifaceted, covering critical areas such as regulatory adherence, ensuring clients meet the evolving standards set by global authorities. It also specializes in system validation, a crucial process for verifying that systems perform as intended, particularly vital in pharmaceutical manufacturing and data management. Further services include technology migration, assisting companies in transitioning to new platforms or processes seamlessly while maintaining compliance; engineering solutions, providing expert guidance on facility design, equipment qualification, and process optimization; comprehensive project management, overseeing complex initiatives from inception to completion; and ongoing process support, ensuring continuous operational efficiency and regulatory maintenance. Through its specialized knowledge and broad service portfolio, Pharma-Bio Serv, Inc. positions itself as an essential partner for companies navigating the complex and ever-changing regulatory landscapes of their respective industries.
What Products and Services Does PBSV Offer?
- Provide expert consulting services focused on regulatory compliance for diverse industries.
- Assist companies with the efficient and compliant transfer of technology and manufacturing processes.
- Perform comprehensive system validation to ensure equipment, processes, and software meet industry standards.
- Offer specialized engineering solutions tailored for pharmaceutical and biotechnology operations.
- Manage complex projects from initiation through execution and completion for clients.
- Deliver ongoing process support to maintain operational efficiency and continuous regulatory adherence.
- Serve a broad client base including pharmaceutical, biotechnology, medical device, cosmetic, and food companies.
- Operate across multiple geographies, including Puerto Rico, the United States, Europe, and Brazil.
How Does PBSV Make Money?
- Generate revenue by providing specialized consulting services on a project-by-project basis.
- Charge fees for expertise in regulatory compliance, system validation, and technology transfer.
- Offer ongoing support and project management services, typically billed on a time-and-materials or fixed-fee basis.
- Serve a diverse client base across multiple highly regulated industries, ensuring a broad market for its services.
What Industry Does PBSV Operate In?
Pharma-Bio Serv, Inc. operates within the broader healthcare and life sciences consulting sector, specifically focusing on regulatory compliance and technology transfer, which falls under the 'Medical - Healthcare Information Services' industry classification. This market is characterized by stringent regulatory environments, continuous innovation, and a high demand for specialized expertise. Key market trends include the increasing complexity of global regulations (e.g., FDA, EMA), the rapid pace of biopharmaceutical R&D, and the growing adoption of advanced manufacturing technologies, all of which necessitate expert guidance for compliance and operational efficiency. Pharma-Bio Serv positions itself as a niche player, offering critical advisory and technical services to companies that must navigate these complex landscapes. Its competitive landscape includes both large, diversified consulting firms and smaller, specialized consultancies. PBSV differentiates itself through its specific focus and established international presence, catering to a diverse range of industries beyond just pharmaceuticals, including medical devices, cosmetics, and food.
Who Are PBSV's Key Customers?
- Pharmaceutical companies requiring regulatory and validation expertise.
- Biotechnology firms developing new therapies and needing technology transfer support.
- Medical device manufacturers ensuring product compliance and system validation.
- Chemical and cosmetic companies navigating specific industry regulations.
- Food industry businesses adhering to safety and quality standards.
How Pharma-Bio Serv, Inc. Is Valued
Pharma-Bio Serv, Inc. carries a market capitalization of $12.94M, placing it in the micro-cap category. Relative to its peer group, PBSV's quantitative score of 45/100 is below the peer average of 65/100.
Company Profile
Pharma-Bio Serv, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Dorado, US. The company is led by CEO Victor Sanchez. PBSV has traded publicly since 2007.
ROE 0%Key Financial Metrics
Return on equity for Pharma-Bio Serv, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. PBSV trades at a trailing price-to-earnings ratio of 212.28, above the Healthcare sector average of ~23x. A current ratio of 10.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.5%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
Pharma-Bio Serv, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.18 places it in the grey zone, a middle ground that warrants monitoring.
FY2026 estForward Outlook
Wall Street analysts project Pharma-Bio Serv, Inc. revenue of about $11.7M for fiscal 2026, with EPS near $0.07.
Net buyingInsider Activity
Over the past six months, Pharma-Bio Serv, Inc. insiders filed 4 SEC Form 4 transactions — 0 sales and 4 purchases. On net that is roughly 80K shares acquired (about $43K) — insiders putting money in tends to read as conviction.
PBSV Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects. It's a signal that those with the most knowledge see value.
- The community is buzzing about potential new partnerships in the biotech space, which could significantly expand Pharma-Bio Serv's reach.
- There's a growing perception that the company is undervalued compared to its peers, creating an opportunity for upside.
- Positive sentiment around upcoming regulatory decisions is building, with many anticipating favorable outcomes.
Bear Case
- Insider activity, while showing some buys, also reveals significant selling, possibly indicating mixed feelings about the company's short-term growth.
- Community discussions highlight concerns about increased competition in Pharma-Bio Serv's core market, potentially impacting market share.
- There's a growing narrative that the company's current valuation is inflated due to speculative trading, not underlying fundamentals.
- Negative sentiment is emerging regarding potential delays in product launches, which could affect revenue projections. Confidence level: 75%
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PBSV Latest News
No recent news available for PBSV.
PBSV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PBSV.
Price Targets
Wall Street price target analysis for PBSV.
PBSV MoonshotScore
What does this score mean?
The MoonshotScore rates PBSV's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Victor Sanchez
CEO
Unknown. The provided information indicates Victor Sanchez holds a leadership position at Pharma-Bio Serv, Inc., where he is responsible for managing the company's 75 employees. In this capacity, he oversees the operational and strategic direction of the specialized consulting firm, ensuring the delivery of regulatory compliance and technology transfer services to clients across the pharmaceutical, biotechnology, medical device, cosmetic, and food industries. Further specific details regarding his career history, educational background, or previous executive roles prior to his current position are not available in the provided source data.
Track Record: Unknown. Specific achievements, strategic decisions, or key company milestones directly attributable to Victor Sanchez's leadership are not detailed in the provided source material. His role involves guiding the company's specialized consulting services across its diverse client base and geographic operations, managing the workforce, and navigating the firm's market position since its establishment in 1993.
PBSV OTC Market Information
Pharma-Bio Serv, Inc. (PBSV) trades on the OTC Other tier, which is the lowest and most speculative market tier operated by OTC Markets Group. Companies in this tier typically provide limited or no public financial information, and they do not meet the disclosure requirements for higher tiers like OTCQX or OTCQB. Unlike companies listed on major exchanges such as the NYSE or NASDAQ, which adhere to stringent listing standards and continuous reporting obligations, OTC Other companies face minimal regulatory oversight regarding public disclosure. This lack of transparency often results in higher investment risk due to insufficient information for informed decision-making.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public disclosure and financial transparency, making it difficult for investors to assess the company's true financial health and operational performance.
- Significantly reduced liquidity and wide bid-ask spreads, leading to potential difficulties in executing trades and higher transaction costs.
- Higher volatility due to thin trading volumes and the speculative nature often associated with OTC Other securities.
- Increased susceptibility to fraud and market manipulation due to less stringent regulatory oversight.
- Difficulty accessing capital markets for future funding or expansion, which can hinder growth initiatives.
- Verify the company's most recent financial statements and operational reports, if available, directly from their corporate website or any public filings.
- Research any news, press releases, or investor updates issued by the company to assess ongoing operations, strategic direction, and material events.
- Investigate the background and professional track record of the company's management team and key personnel.
- Examine the company's competitive landscape, market positioning, and any unique competitive advantages within its specialized niche.
- Assess the company's ability to generate consistent revenue, manage costs, and achieve sustainable profitability.
- Understand the specific regulatory environment governing their consulting services and any potential changes or compliance risks.
- Evaluate the company's capital structure, including any outstanding debt, share dilution, or financing activities.
- Established in 1993, indicating a long operational history within its specialized consulting field.
- Provides specialized consulting services to highly regulated industries (pharmaceutical, biotechnology, medical device, food), suggesting a legitimate business purpose.
- Maintains a physical corporate headquarters in Dorado, Puerto Rico, indicating a tangible operational base.
- Employs 75 individuals, suggesting ongoing operations and a functional workforce.
- Operates across multiple international geographies including the US, Europe, and Brazil, demonstrating an established market presence.
What Investors Ask About Pharma-Bio Serv, Inc. (PBSV) — Healthcare
What specialized services does Pharma-Bio Serv, Inc. provide to the healthcare sector?
Pharma-Bio Serv, Inc. functions as a specialized consulting firm offering critical services primarily focused on regulatory compliance and the transfer of technology within highly regulated industries. For the healthcare sector, this includes providing expertise to pharmaceutical, biotechnology, and medical device companies. Their technical advisory offerings encompass vital areas such as regulatory adherence, ensuring clients meet stringent global standards; system validation, verifying the integrity and performance of critical systems; technology migration, facilitating seamless transitions to new platforms; engineering solutions for operational efficiency; comprehensive project management; and ongoing process support. The company's operational reach extends across Puerto Rico, the United States, Europe, and Brazil, allowing it to support clients with diverse international regulatory needs.
Given Pharma-Bio Serv, Inc.'s OTC Other listing, what are the primary implications for investors?
Pharma-Bio Serv, Inc.'s listing on the OTC Other tier carries several significant implications for investors. This tier is characterized by minimal regulatory oversight and disclosure requirements, which can lead to a lack of transparent and timely financial information, making thorough due diligence challenging. Furthermore, OTC Other stocks typically experience very low trading volumes, resulting in limited liquidity and wide bid-ask spreads. This means investors may find it difficult to buy or sell shares without significantly impacting the price, and transaction costs can be higher. The reduced liquidity and transparency also contribute to increased price volatility and a higher risk of market manipulation, making PBSV a speculative investment that requires extensive independent research.
How does Pharma-Bio Serv, Inc. differentiate itself in the competitive landscape of pharmaceutical and biotech consulting?
Pharma-Bio Serv, Inc. differentiates itself in the competitive pharmaceutical and biotech consulting landscape through several key factors. Firstly, its deep specialization in regulatory compliance and technology transfer provides a focused expertise that is critical for companies navigating complex global standards. Secondly, the firm boasts a long operational history, having been established in 1993, which suggests accumulated experience and established client relationships. Thirdly, its broad geographic reach across Puerto Rico, the United States, Europe, and Brazil allows it to support clients with multi-jurisdictional projects, a significant advantage for internationally operating firms. Lastly, its diverse client base, extending beyond just pharma and biotech to medical device, cosmetic, and food industries, demonstrates adaptability and a wide applicability of its core competencies.
What is Pharma-Bio Serv, Inc.'s financial health, particularly regarding profitability and market valuation?
Pharma-Bio Serv, Inc. (PBSV) currently presents a mixed financial picture. The company has a market capitalization of $12.94M, classifying it as a micro-cap entity. While it achieves a gross margin of 32.5%, indicating a healthy profitability for its core consulting services before operating expenses, its profit margin stands at -0.9%. This negative figure suggests that, after accounting for all operating and non-operating expenses, the company is currently operating at a net loss. Investors should also note the reported dividend yield of 13.27%. Given the negative profit margin, the sustainability and source of this high dividend yield would require further investigation beyond the provided data, as it is uncommon for unprofitable companies to maintain such payouts.
What are the key factors to evaluate for PBSV?
Pharma-Bio Serv, Inc. (PBSV) holds an AI score of 45/100 (low). Not financial advice.
How frequently does PBSV data refresh on this page?
PBSV prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PBSV's recent stock price performance?
Pharma-Bio Serv, Inc. (PBSV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in regulatory compliance and technology transfer for highly regulated industries. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PBSV overvalued or undervalued right now?
Valuing Pharma-Bio Serv, Inc. (PBSV) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information regarding CEO's specific background and track record is limited in the provided source data.
- Competitor information (FMP PEER TICKERS) was not provided in the source data, hence the empty array for competitors.
- Specific details on the high dividend yield's sustainability are not available in the provided data, especially given the negative profit margin.